Main Article Content


Background: Rheumatoid arthritis is a persistent, immune-mediated disorder that causes pain, edema, and inflammation in the joints. A genetic history that is high in risk, when paired with genomic markers and environmental exposures, triggers a series of actions that not only results in synovitis and arthritis, but also affects a great number of organs that are not related to the joints. The identification of novel autoantibodies playing key roles in different stages of disease remains an issue of interest for RA. Therefore, autoantibodies are necessary to assist in making a diagnosis and prediction more quickly in RA. Anti-Carbamylated Protein antibodies are a different class of anti- transformed protein antibody that is often found in the blood of RA patients. Objective: Rheumatoid arthritis has a recently discovered biomarker, which is an antibody called anti-carbamylated protein (CarP). Our aim is to evaluate the usefulness of anti-CarP as a diagnostic tool for RA. Participants and methods: The study conducted on 60 people diagnosed with RA as well as 60 people who served as healthy controls. Both the disease activity score (DAS28) and the health assessment questionnaire (HAQ) were evaluated. Estimates were made based on laboratory examinations such as ESR and rheumatoid factor (RF). Anti-CarP and Anti-CCP antibodies were measured by enzyme-linked immune-sorbent assay. Results:Anti-CarP levels were considerably higher in the patients with RA compared to the group that provided as a control (p > 0.000). Therefore, the sensitivity and specificity for anti-CarP antibodies were 39% and 98% respectively, while the sensitivity and specificity for anti-CCP antibodies were 83% and 95% respectively, and for RF were 68% and 83% respectively. The area under the curve (AUC) for anti-CarP antibodies was 0.67.


Anti-CarP antibodies had comparatively lower sensitivity and slightly higher specificity than Anti-CCP.These findings suggest that anti-CarP antibodies works as an additional role in the diagnosis of RA.


Rheumatoid Arthritis, Anti-Carbamylated Protein, Anti-Citrullinated Peptide, Rheumatoid Factor

Article Details

How to Cite
A Ali, G. ., & S Abbas, T. . (2022). Anti-Carbamylated Protein Antibody Test Accuracy In Some Iraqi Patients With Rheumatoid Arthritis . Medical Science Journal for Advance Research, 3(4), 171–178.


  1. Angelotti, F., Parma, A., Cafaro, G., Capecchi, R., Alunno, A., & Puxeddu, I. (2017). One year in review 2017: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol, 35(3), 368-78
  2. Allam, S. I., Sallam, R. A., Elghannam, D. M., & El-Ghaweet, A. I. (2019). Clinical significance of serum B cell chemokine (CXCL13) in early rheumatoid arthritis patients. The Egyptian Rheumatologist, 41(1), 11-14
  3. Castellanos-Moreira, R., Rodriguez-Garcia, S. C., Cabrera-Villalba, S., Gomara, M. J., Salvador, G., Ruiz-Esquide, V., ... & Sanmarti, R. (2020). Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 12, 1759720X20978139
  4. D.A. Hussein, S.A. El Bakry, N.A. Morshedy, S.E. Ibrahim, H.M. Sakr, R.A. Abo-Shady Role of cartilage oligomeric matrix protein (COMP) as a prognostic biomarker in follow-up of early rheumatoid arthritis patients: correlation to musculoskeletal ultrasonographic findings Egypt Rheumatol, 40 (4) (2018), pp. 221-226
  5. Deane, K. D., Demoruelle, M. K., Kelmenson, L. B., Kuhn, K. A., Norris, J. M., & Holers, V. M. (2017). Genetic and environmental risk factors for rheumatoid arthritis. Best practice & research Clinical rheumatology, 31(1), 3-18.
  6. Elsayed, S. A., Esmail, M. A., Ali, R. M., & Mohafez, O. M. (2019). Diagnostic and prognostic value of anti-CarP antibodies in a sample of Egyptian rheumatoid arthritis patients. Clinical rheumatology, 38(10), 2683-2689.
  7. Erre, G. L., Mundula, N., Colombo, E., Mangoni, A. A., Sechi, L. A., Oggiano, M., ... & Carru, C. (2019). Diagnostic Accuracy of Anticarbamylated Protein Antibodies in Established Rheumatoid Arthritis: A Monocentric Cross‐Sectional Study. ACR Open Rheumatology, 1(7), 433-439.‏
  8. M. Brink, M.K. Verheul, J. Ronnelid, E. Berglin, R. Holmdahl, R.E. Toes, et al.Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage Arthritis Res. Ther., 17 (2015), p. 25
  9. Yap, H. Y., Tee, S. Z. Y., Wong, M. M. T., Chow, S. K., Peh, S. C., & Teow, S. Y. (2018). Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development. Cells, 7(10), 161.
  10. Li, L., Deng, C., Chen, S., Zhang, S., Wu, Z., Hu, C., ... & Li, Y. (2016). Meta-analysis: diagnostic accuracy of anti-carbamylated protein antibody for rheumatoid arthritis. PloS one, 11(7), e0159000.‏
  11. Shi, J., van Steenbergen, H. W., van Nies, J. A., Levarht, E. W., Huizinga, T. W., van der Helm-van Mil, A., ... & Trouw, L. A. (2015). The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. Arthritis research & therapy, 17(1), 1-6.‏
  12. Shi, J., Willemze, A., Janssen, G. M., van Veelen, P. A., Drijfhout, J. W., Cerami, A., ... & Toes, R. E. (2013). Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the ‘AMC-Senshu’method. Annals of the rheumatic diseases, 72(1), 148-150.‏
  13. Shaker, O. G., El-Demellawy, H. H., Salem, M. N., & Eesa, N. N. (2016). Methylene tetrahydrofolate reductase (MTHFR) gene polymorphisms in rheumatoid arthritis patients: correlation with serum osteopontin levels and disease activity. The Egyptian Rheumatologist, 38(4), 283-288.‏
  14. Smolen, J. S., Aletaha, D., Barton, A., Burmester, G. R., Emery, P., Firestein, G. S., Kavanaugh, A., McInnes, I. B., Solomon, D. H., Strand, V., & Yamamoto, K. (2018). Rheumatoid arthritis. Nature Reviews Disease Primers, 4, 1–23.
  15. Verheul M, van Erp S, van der Woude D, Levarht E, Mallat M, Verspaget H, et al. Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation;renal failure, smoking and chronic inflammation. Ann Rheum Dis. 2016;0:1–2.
  16. Verheul, M. K., Böhringer, S., van Delft, M. A., Jones, J. D., Rigby, W. F., Gan, R. W., ... & Trouw, L. A. (2018). Triple positivity for anti–citrullinated protein autoantibodies, rheumatoid factor, and anti–carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: implications for very early identification of at‐risk individuals. Arthritis & rheumatology, 70(11), 1721-1731.‏
  17. van Delft, M. A., & Huizinga, T. W. (2020). An overview of autoantibodies in rheumatoid arthritis. Journal of autoimmunity, 110, 102392.
  18. Trouw, L. A., Pickering, M. C., & Blom, A. M. (2017). The complement system as a potential therapeutic target in rheumatic disease. Nature Reviews Rheumatology, 13(9), 538–547.
  19. Pecani, A., Alessandri, C., Spinelli, F. R., Priori, R., Riccieri, V., Di Franco, M., ... & Conti, F. (2016). Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases. Arthritis research & therapy, 18(1), 1-8.‏